
Suraksha Diagnostic (SURAKSHA) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
725.9M
Gross Profit
638.4M
87.94%
Operating Income
133.8M
18.43%
Net Income
91.8M
12.64%
EPS (Diluted)
₹1.80
Balance Sheet Metrics
Total Assets
3.3B
Total Liabilities
1.2B
Shareholders Equity
2.1B
Debt to Equity
0.59
Cash Flow Metrics
Operating Cash Flow
148.5M
Free Cash Flow
64.6M
Revenue & Profitability Trend
Suraksha Diagnostic Income Statement From 2022 to 2025
Metric | 2025 | 2024 | 2023 | 2022 |
---|---|---|---|---|
Revenue | 2.5B | 2.2B | 1.9B | 2.2B |
Cost of Goods Sold | 295.2M | 272.5M | 274.0M | 604.0M |
Gross Profit | 2.2B | 1.9B | 1.6B | 1.6B |
Gross Margin % | 88.3% | 87.5% | 85.6% | 72.9% |
Operating Expenses | ||||
Research & Development | - | - | - | - |
Selling, General & Administrative | 502.3M | 379.3M | 357.1M | 273.6M |
Other Operating Expenses | 401.7M | 375.3M | 358.4M | 328.8M |
Total Operating Expenses | 904.1M | 754.6M | 715.5M | 602.3M |
Operating Income | 496.4M | 408.3M | 157.8M | 366.5M |
Operating Margin % | 19.7% | 18.7% | 8.3% | 16.4% |
Non-Operating Items | ||||
Interest Income | 35.6M | 34.9M | 28.6M | 19.9M |
Interest Expense | 83.9M | 87.9M | 90.6M | 88.5M |
Other Non-Operating Income | - | - | - | - |
Pre-tax Income | 414.1M | 314.5M | 67.5M | 280.1M |
Income Tax | 104.3M | 83.3M | 6.8M | 71.9M |
Effective Tax Rate % | 25.2% | 26.5% | 10.1% | 25.7% |
Net Income | 309.8M | 231.3M | 60.6M | 208.2M |
Net Margin % | 12.3% | 10.6% | 3.2% | 9.3% |
Key Metrics | ||||
EBITDA | 878.6M | 761.6M | 499.1M | 666.6M |
EPS (Basic) | ₹5.97 | ₹4.54 | ₹1.25 | ₹4.00 |
EPS (Diluted) | ₹5.97 | ₹4.54 | ₹1.25 | ₹4.00 |
Basic Shares Outstanding | 52080758 | 52080758 | 52080758 | 52080758 |
Diluted Shares Outstanding | 52080758 | 52080758 | 52080758 | 52080758 |
Income Statement Trend
Suraksha Diagnostic Balance Sheet From 2022 to 2025
Metric | 2025 | 2024 | 2023 | 2022 |
---|---|---|---|---|
Assets | ||||
Current Assets | ||||
Cash & Equivalents | 22.5M | 25.2M | 21.6M | 31.9M |
Short-term Investments | 158.0M | 490.8M | 501.2M | 381.0M |
Accounts Receivable | 138.1M | 88.8M | 46.8M | 67.3M |
Inventory | 80.5M | 66.8M | 61.6M | 62.2M |
Other Current Assets | 26.6M | - | - | - |
Total Current Assets | 471.5M | 724.5M | 680.5M | 630.0M |
Non-Current Assets | ||||
Property, Plant & Equipment | 1.4B | 1.2B | 936.0M | 937.3M |
Goodwill | 19.9M | 10.8M | 14.5M | 17.5M |
Intangible Assets | 19.9M | 10.8M | 14.5M | 17.5M |
Long-term Investments | - | - | - | - |
Other Non-Current Assets | -1.0K | - | - | - |
Total Non-Current Assets | 2.9B | 2.3B | 2.1B | 2.1B |
Total Assets | 3.3B | 3.0B | 2.8B | 2.8B |
Liabilities | ||||
Current Liabilities | ||||
Accounts Payable | 136.4M | 143.9M | 140.4M | 137.2M |
Short-term Debt | 147.9M | 149.9M | 165.1M | 166.6M |
Current Portion of Long-term Debt | - | - | - | - |
Other Current Liabilities | 1.0K | - | - | - |
Total Current Liabilities | 427.2M | 394.1M | 383.4M | 383.5M |
Non-Current Liabilities | ||||
Long-term Debt | 741.0M | 754.9M | 803.6M | 831.4M |
Deferred Tax Liabilities | 54.5M | 53.9M | 65.8M | 83.4M |
Other Non-Current Liabilities | 1.0K | - | - | - |
Total Non-Current Liabilities | 805.8M | 816.5M | 873.9M | 917.8M |
Total Liabilities | 1.2B | 1.2B | 1.3B | 1.3B |
Equity | ||||
Common Stock | 104.2M | 69.0M | 69.0M | 69.0M |
Retained Earnings | 1.5B | 1.2B | 990.3M | 889.4M |
Treasury Stock | - | - | - | - |
Other Equity | - | - | - | - |
Total Shareholders Equity | 2.1B | 1.8B | 1.6B | 1.5B |
Key Metrics | ||||
Total Debt | 888.9M | 904.8M | 968.7M | 998.0M |
Working Capital | 44.4M | 330.4M | 297.1M | 246.6M |
Balance Sheet Composition
Suraksha Diagnostic Cash Flow Statement From 2022 to 2025
Metric | 2025 | 2024 | 2023 | 2022 |
---|---|---|---|---|
Operating Activities | ||||
Net Income | 414.1M | 314.5M | 67.5M | 280.1M |
Depreciation & Amortization | - | - | - | - |
Stock-Based Compensation | 2.1M | - | - | - |
Working Capital Changes | -99.1M | -40.9M | 41.8M | -41.2M |
Operating Cash Flow | 365.1M | 326.3M | 171.2M | 305.7M |
Investing Activities | ||||
Capital Expenditures | -418.8M | -429.2M | -125.1M | -189.0M |
Acquisitions | - | - | - | - |
Investment Purchases | -12.6M | -413.7M | -410.5M | -315.0M |
Investment Sales | - | 461.1M | 302.2M | 54.1M |
Investing Cash Flow | -431.4M | -381.9M | -233.3M | -450.0M |
Financing Activities | ||||
Share Repurchases | - | - | - | - |
Dividends Paid | - | - | - | - |
Debt Issuance | 0 | 5.0M | 20.5M | 95.9M |
Debt Repayment | -28.1M | -58.7M | -70.7M | -70.0M |
Financing Cash Flow | -27.1M | -46.7M | -50.2M | 26.0M |
Free Cash Flow | 213.4M | 157.9M | 309.3M | 385.7M |
Net Change in Cash | -93.4M | -102.2M | -112.3M | -118.3M |
Cash Flow Trend
Suraksha Diagnostic Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
46.63
Forward P/E
31.82
Price to Book
7.33
Price to Sales
5.87
PEG Ratio
2.58
Profitability Ratios
Profit Margin
12.62%
Operating Margin
19.43%
Return on Equity
15.14%
Return on Assets
9.54%
Financial Health
Current Ratio
1.10
Debt to Equity
42.28
Per Share Data
EPS (TTM)
₹6.38
Book Value per Share
₹40.56
Revenue per Share
₹50.90
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
suraksha | 16.1B | 46.63 | 7.33 | 15.14% | 12.62% | 42.28 |
Dr. Lal PathLabs | 266.1B | 52.40 | 12.09 | 22.08% | 20.29% | 7.14 |
Syngene | 250.3B | 48.97 | 5.30 | 10.50% | 13.61% | 12.23 |
Vimta Labs | 34.7B | 46.52 | 8.69 | 17.78% | 19.93% | 2.25 |
Krsnaa Diagnostics | 25.3B | 31.53 | 2.81 | 8.79% | 10.84% | 23.06 |
Qualitek Labs | 4.8B | 58.45 | 4.77 | 12.27% | 8.97% | 37.74 |
Financial data is updated regularly. All figures are in the company's reporting currency.